Get the Stockscreener App
1.28
0.79%
0.01
After Hours:
1.25
-0.03
-2.34%
An 2 Therapeutics Inc stock is traded at $1.28, with a volume of 97,238.
It is up +0.79% in the last 24 hours and up +21.90% over the past month.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
See More
Previous Close:
$1.27
Open:
$1.27
24h Volume:
97,238
Relative Volume:
0.68
Market Cap:
$34.98M
Revenue:
-
Net Income/Loss:
$-37.38M
P/E Ratio:
-1.0323
EPS:
-1.24
Net Cash Flow:
$-35.50M
1W Performance:
+1.59%
1M Performance:
+21.90%
6M Performance:
-5.19%
1Y Performance:
+23.08%
1-Day Range:
$1.25
$1.3299
1-Week Range:
$1.05
$1.3299
52-Week Range:
$0.975
$1.675
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Name
An 2 Therapeutics Inc
Sector
Industry
Phone
(650) 331-9090
Address
1800 EL CAMINO REAL, SUITE D, MENLO PARK
Compare ANTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
1.28 | 33.61M | 0 | -37.38M | -35.50M | -1.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-03-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Apr-02-24 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-13-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-12-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-12-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-12-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-04-24 | Initiated | JMP Securities | Mkt Outperform |
| Jul-18-22 | Resumed | Oppenheimer | Outperform |
View All
An 2 Therapeutics Inc Stock (ANTX) Latest News
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline - GlobeNewswire
Xilio Therapeutics Announces Initiation of Phase 2 Trial - GlobeNewswire
Both 300mg and 600mg Doses Show Rapid Improvement: Dianthus's Claseprubart Succeeds in Phase 2 gMG Study - Stock Titan
Breaking: Biotech Dianthus Ready to Unveil Critical Phase 2 Results for Novel Autoimmune Drug Claseprubart - Stock Titan
Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent (NASDAQ:MNPR) - Seeking Alpha
Cognition Therapeutics, Inc. Achieves 75% Enrollment in Phase 2 START Study for Early Alzheimer’s Disease Treatment - Quiver Quantitative
Hoth Therapeutics Inc. Eyes Future Growth Amidst Current Market Dynamics - StocksToTrade
Levi & Korsinsky Notifies Shareholders of Capricor Therapeutics, Inc.(CAPR) of a Class Action Lawsuit and an Upcoming Deadline - Morningstar
United Therapeutics Corporation announces Teton-2 pivotal study of Tyvaso meets primary endpoint for the treatment of idiopathic pulmonary fibrosis - MarketScreener
95.6mL Lung Function Improvement: United Therapeutics' Tyvaso Achieves Breakthrough in IPF Treatment Trial - Stock Titan
Relmada Therapeutics, Inc. (RLMD) Reports 91% Response Rate in Phase 2 Bladder Cancer Study - Insider Monkey
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer - GlobeNewswire
Serina Therapeutics Announces FDA Feedback Supports - GlobeNewswire
BlossomHill Therapeutics Announces First Patient Dosed in Expansion Cohorts of the Phase 1/2 SOLARA Trial, Evaluating BH-30643 in Advanced EGFR-mutant Non-Small Cell Lung Cancer - GlobeNewswire
Novel Brain Hormone Therapy PT00114 Targets Stress Response: Protagenic's Phase 1 Trial Advances - Stock Titan
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders - ACCESS Newswire
Mountain Crest Acquisition Corp. II/Better Therapeutics, Inc. Class Action – Important Settlement Information - Business Wire
Viking Therapeutics: Phase 2 Oral Obesity Data Affirms Bear Case, Downgrade To Sell (VKTX) - Seeking Alpha
Viking Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - PR Newswire
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) - GlobeNewswire
Capricor Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationCAPR - The Malaysian Reserve
Plus Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Xilio Therapeutics shares fall 2.52% intraday after announcing updated Phase 2 data for vilastobart. - AInvest
Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease - PR Newswire
Candel Therapeutics, Inc. SEC 10-Q Report - TradingView
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-Q Report - TradingView
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results - Yahoo Finance
Werewolf Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics, Inc. SEC 10-Q Report - TradingView
Allogene Therapeutics Advances Pivotal Phase 2 ALPHA3 Trial for Cema-Cel in Large B-Cell Lymphoma and Initiates Phase 1 Trials for Autoimmune Disease and Renal Cell Carcinoma - Quiver Quantitative
Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - simplywall.st
Cognition Therapeutics Receives End-of-Phase 2 Meeting - GlobeNewswire
Breakthrough Alzheimer's Drug Zervimesine Advances to Phase 3 with Novel Blood Test Strategy - Stock Titan
BridgeBio Oncology Therapeutics, Inc. Completes Business Combination with Helix Acquisition Corp. II, Secures $382 Million in Gross Proceeds - Quiver Quantitative
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile
Windtree Therapeutics, Inc. Reports Positive Interim Analysis for Istaroxime in Phase 2 Study of Cardiogenic Shock - Quiver Quantitative
BioXcel Therapeutics Completes Phase 3 Trial, Awaits FDA Decision - StocksToTrade
Apogee Therapeutics, Inc. (APGE) Soars on Promising Phase 2 Results for Atopic Dermatitis Drug - MSN
BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia - GlobeNewswire
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - Business Wire
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene Therapy - Yahoo Finance
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis - Newsfile
DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer - Yahoo Finance
Cognition Therapeutics, Inc. Reports Promising Results for Zervimesine in Phase 2 Alzheimer’s and Dementia with Lewy Bodies Studies - Nasdaq
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC - GlobeNewswire
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Ovid Therapeutics (NASDAQ:OVID) Stock Price Down 2% – Time to Sell? - Defense World
Allogene Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Cognition Therapeutics, Inc. (CGTX) Retains Buy Rating on START Study Progress - Yahoo Finance
An 2 Therapeutics Inc Stock (ANTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):